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ABSTRACT: T cell lymphoproliferative disorders continue to be serious manage-
ment problems, and so alternative therapeutic modalities are continuously be-
ing explored. One such strategy involves immunotherapy using the T cell
receptor (TCR) as a target. Specifically we are attempting to develop a T cell
receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-
specific antigen. In this article we will briefly review the rationale for TCR-Id
vaccines, the preclinical models as developed in our laboratory, and a discus-
sion of our current plans for a vaccine trial in mycosis fungoides.
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INTRODUCTION
T cell lymphoproliferative disorders continue to be a serious management prob-
lem. Since only a fraction of patients are cured by standard treatment (radiotherapy
and/or chemotherapy), alternative therapeutic modalities are constantly being ex-
plored. One such strategy involves immunotherapy using the T cell receptor (TCR)
as a target. Specifically we are attempting to develop a T cell receptor idiotype
(TCR-Id)1–4 vaccine because the TCR-Id can serve as a tumor-specific antigen. The
idiotype is a collection of unique determinants found in the hypervariable regions of
antigen receptors. 
In this article we plan to briefly review the general rationale for TCR-Id vaccines,
the preclinical models as developed in our laboratory, and a discussion of our current
plans for a vaccine trial in a specific T cell malignancy known as mycosis fungoides
(MF).5–7
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MYCOSIS FUNGOIDES/CUTANEOUS T CELL LYMPHOMA
There are a variety of T cell tumors (nodal and cutaneous T cell lymphomas and
the T cell leukemias) that could serve as the subject of a TCR-Id vaccine trial. We
have chosen a particular cutaneous T cell lymphoma (CTCL) known as mycosis fun-
goides for our planned vaccine trial. 
MF is a prototypical T cell malignancy for development of vaccine therapy since
it is the most common of the CTCLs with easy accessibility of tumor tissue by skin
or lymph node biopsy. Also, MF has a well-defined natural history with high initial
response rates to conventional therapies but with frequent relapses.5–7 There are no
reliable alternative therapies for patients with recalcitrant or advanced disease. Pa-
tients with generalized thick plaque and/or tumor disease (stage IB-IIB) and patients
with regional lymph node disease (stage IVA) are potential candidates to consider
for vaccine therapy.
RATIONALE FOR VACCINE THERAPY AGAINST THE
TUMOR-SPECIFIC T CELL RECEPTOR
The antigen receptors of T (TCRs) and B (immunoglobulin) cells are unique mo-
lecular targets because the formation of their variable regions requires the recombi-
nation of multiple V, (D), and J germline segments.8 The final antigen receptor is
further modified from the germline through the addition and deletion of junctional
nucleotides in a template-independent manner. In the case of B cells, immunoglob-
ulin can be further modified by somatic mutation. The variable region of the final
product contains a unique sequence known as the CDR 3 region. 
Most malignancies of B and T lymphocytes represent the transformation and ex-
pansion of a single clone, all of which have the same antigen receptor. Therefore, the
T cell receptor of the malignant tumor clone could serve as a unique tumor-specific
target.
We and others have had extensive experience in testing this hypothesis. Numer-
ous studies have exploited the idiotype on B cell malignancies as a target for therapy
in animal models and in human patients.9–22 Passive therapy with monoclonal anti-
bodies against the tumor idiotype has resulted in a high frequency of, and occasional
long-term regression of, B cell lymphomas in humans.23 Active vaccination with tu-
mor idiotype proteins has led to immune responses in patients against their own B
cell tumors. These responses have been associated with an improved clinical
outcome.12
There are several differences between the antigen receptors on T cells (TCRs) and
B cells (BCRs) that predict that the TCR would provide an even better target for ther-
apy. In contrast to the BCRs, the TCR does not undergo somatic mutation.24 This
makes it much less likely that T cell tumors would escape from immunotherapy di-
rected against their receptor. Unlike the BCR, there is no secreted form of the TCR,
and therefore there is no decoy receptor in the serum of tumor-bearing subjects. Fi-
nally, there is evidence that ligands for the TCR have a direct antiproliferative effect
on T cell tumors.25
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ANIMAL MODELS OF TCR-ID VACCINATION
Protein Vaccination
Passive immunotherapy with Vβ8.2- (the β chain of the disease-causing T cell
clone) specific antibody in a mouse autoimmune disease model (EAE-multiple scle-
rosis) prevented development of, and suppressed ongoing, disease.26–29 In this mod-
el, vaccination with this β chain also showed protection.30–33 Passive TCR-Id
antibody therapy has also been shown to be effective in T cell malignancy, in both a
mouse model and a human patient.34,35
Based on the above rationale, we developed a TCR-Id protein vaccine in the
mouse C6VL thymoma model. It required extensive effort to produce enough tumor-
specific TCR protein for vaccination. The problem was overcome by developing a
mammalian expression vector encoding both the α and β chain of the TCR linked to
a membrane-anchoring region of the decay accelerating factor (DAF, a phosphatidyl
inositol–linked surface molecule).36 After selecting for cells with a high level of
TCR expression, the protein could be released from the membrane by a specific
phospholipase enzyme.
When mice were vaccinated with TCR protein linked to KLH (carrier protein)
and mixed with Syntax adjuvant formulation (SAF), they were protected from chal-
lenge with the tumor (FIG. 1).1,2 Strong antibody responses to the specific TCR were
generated. However, the evidence suggests that a CD8 T cell response is the mode
of protective immunity. Depletion of CD8 T cells in the vaccinated mice abrogated
the protective response. Protection against tumor challenge in this model system re-
quired both coupling of the TCR to the KLH carrier protein and the use of an immu-
nologic adjuvant.
FIGURE 1. TCR vaccines protect mice against C6VL. Tumor challenge protection
requires KLH and SAF. PBS, phosphate-buffered saline; SAF, Syntax adjuvant formulation.
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Adenovirus Vaccination
The difficulty of making TCR protein for vaccination makes the approach cur-
rently inapplicable on a wide scale, as would be necessary for human trials.
We then explored the merit of TCR-Id encoding adenovirus for use in this vacci-
nation model. This involved recombination between a plasmid encoding the TCR
genes and a plasmid encoding replication-deficient adenoviral genes. The final ade-
FIGURE 3. Protection against C6VL in mice vaccinated with TCR/HuCR/Ad. Tu-
mor challenge with adenoviral vaccine requires human constant region. (Reprinted by per-
mission from Wong & Levy.3)
FIGURE 2. Production of recombinant adenovirus.
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novirus vaccine required about four weeks to produce (FIG. 2).3 We were then able
to show specific expression of the TCR in adenovirus-infected cells. When the
C6VL variable regions were coupled with human constant regions, the viral vaccine
showed protection against tumor challenge (FIG. 3).3 We also showed the generation
of a specific antibody response to the tumor-specific TCR-Id and abrogation of pro-
tection with CD8 depletion (FIG. 4).3 In this model, protection required linkage of
the mouse variable regions to human TCR constant regions and was CD8 T cell
dependent.
STRATEGIES FOR TCR VACCINATION IN HUMANS
TCR-Id vaccination in humans becomes a more complicated problem because of
the variability of usage of the different TCR α and β chains. Previously we have
shown that TCR Vβ usage is nonpreferential in MF.37 Thus many α and β TCR fam-
ily-specific primers might be needed for cloning of TCR genes from all human MF
samples. Although this approach is feasible, there exists an easier method known as
RACE (rapid amplification of cDNA ends).38–40 This method involves reverse tran-
scribing the TCR genes using constant region primers and creating a homopolymeric
tail on the 5′ end so as to avoid usage of multiple family-specific primers for PCR
amplification. A further modification of this technique known as SMART PCR (de-
veloped and marketed by Clontech Laboratories)41 is now being used in our labora-
tory for cloning of whole TCR α and β variable regions.42–44 This method also adds
a consensus primer to the 5′ end of the cDNA. In addition it takes advantage of the
touchdown PCR strategy.45
In our hands, this method yields complete α and β variable regions with fewer
cycles of PCR compared to traditional RACE, when performed on MF samples. We
are able to obtain monoclonal bands and then, by sequencing, identify our unique
FIGURE 4. Tumor protection is dependent on CD8+ cells. (Reprinted by permission
from Wong & Levy.3)
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clonal receptor. This methodology is thus validated for the purpose of cloning TCRs
from tumor populations (FIGS. 5–8). 
Our current plans involve use of a TCR-Id vaccine in MF patients. This phase I/
II study will assess safety and feasibility. In addition, we will measure patient sera
for evidence of a TCR-Id–specific immune response. Based on the mouse model we
plan to use xenogeneic (mouse) constant regions coupled to human TCR variable re-
gions for the vaccines.
Important questions remain with regard to the specific details of this trial. One of
the most crucial issues is to determine the best vector for delivery of a TCR vaccine.
Would adjuvant be required in humans with the use of a xenogeneic (mouse) con-
FIGURE 5. Smart PCR cDNA synthesis. The RT reaction contains both the smart
primer and an oligo dT primer along with total mRNA.
FIGURE 6. Smart PCR. Cloning and sequencing of PCR band.
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stant region? What patient populations of MF would be most suitable for pilot stud-
ies? Should they receive standard treatment followed by vaccine, or upfront vaccine
therapy?
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